August 28, 2016 11:47 PM ET

Pharmaceuticals

Company Overview of Ritter Pharmaceuticals, Inc.

Company Overview

Ritter Pharmaceuticals, Inc. develops novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which is under development for the reduction of symptoms associated with lactose intolerance. The company’s RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon, thereby adapting the gut microbiome to assist in digesting the lactose that reaches the large intestine. Its RP-G28 has been studied in a Phase 2a clinical trial. The company was formerly known as Ritter Natural Sciences, LLC and changed its name to Ritter Pharmaceuticals, Inc. in September 20...

1880 Century Park East

Suite 1000

Los Angeles, CA 90067

United States

Founded in 2004

8 Employees

Phone:

310-203-1000

Fax:

310-919-1600

Key Executives for Ritter Pharmaceuticals, Inc.

Chief Executive Officer and Director
Age: 56
Total Annual Compensation: $348.7K
Co-Founder, President and Director
Age: 33
Total Annual Compensation: $383.3K
Co-Founder, Executive Chairman and Chief Strategic Officer
Age: 66
Total Annual Compensation: $353.2K
Compensation as of Fiscal Year 2015.

Ritter Pharmaceuticals, Inc. Key Developments

Ritter Pharmaceuticals, Inc. Completes Patient Enrollment for its Phase 2B/3 Clinical Trial of its Investigational Compound RP-G28 for the Treatment of Lactose Intolerance

Ritter Pharmaceuticals, Inc. announced that it has completed patient enrollment on schedule for its Phase 2b/3 clinical trial of its investigational compound RP-G28 for the treatment of lactose intolerance. Topline results of the trial are expected to be announced in the first quarter of 2017. The Phase 2b/3 trial is a double-blind, placebo-controlled, three arm, multicenter study evaluating safety, efficacy and tolerability of two dosing regimens of its investigational compound RP-G28 in patients with moderate to severe lactose intolerance symptoms. Enrollment was initiated in March of 2016 and completed within 6-months, achieving the company's projected enrollment milestones. The study aims to evaluate a patient's ability to consume dairy foods post-treatment with improved tolerance and reduced digestive symptoms. A total of 377 subjects were enrolled in the trial with 18 clinical sites participating throughout the United States. Patients undergo a 30-day treatment, followed by a 30-day post-treatment evaluation of dairy tolerance. In addition, the study will evaluate each participant's microbiome, expanding knowledge of the effects that RP-G28 may have on adapting the gut microbiota in a beneficial manner.

Ritter Pharmaceuticals, Inc. Announces Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2016

Ritter Pharmaceuticals, Inc. announced unaudited earnings results for the second quarter and six months ended June 30, 2016. For the second quarter 2016, the company reported a net loss attributable to common stockholders of approximately $4,139,472 compared to $2,307,481 for the second quarter of 2015. Basic and diluted net loss per share was $0.48 for the three months ended June 30, 2016 compared to basic and diluted net loss per share of $4.18 for the same period in 2015. Operating loss was $4,156,133 against $2,099,831 a year ago. For the six months, the company reported a net loss attributable to common stockholders of approximately $7,267,922 compared to $3,875,586 for the same period a year ago. Basic and diluted net loss per share was $0.85, compared to basic and diluted net loss per share of $7.62 for the same period in 2015. Operating loss was $7,306,363 against $3,496,130 a year ago.

Ritter Pharmaceuticals, Inc. Announces Earnings Results for the First Quarter 2016

Ritter Pharmaceuticals, Inc. announced earnings results for the first quarter 2016. For the first quarter of 2016, the company reported a net loss attributable to common stockholders of approximately $3.1 million compared to a net loss of approximately $1.6 million for the first quarter of 2015. Basic and diluted net loss per share was $0.36 for the first quarter of 2016 compared to basic and diluted net loss per share of $3.37 for the first quarter of 2015. Research and development expenses totaled approximately $1.9 million for the first quarter of 2016 versus approximately $31,000 for first quarter of 2015. This increase was driven by the preparation of adaptive design Phase 2b/3 clinical trial, which was initiated in March 2016.

Similar Private Companies By Industry

Company Name Region
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States
7 Oaks Pharmaceutical Corp. United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
December 18, 2015
--
 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
NYC2012, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Ritter Pharmaceuticals, Inc., please visit www.ritterpharmaceuticals.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.